Browse
Submit Data
Databases
API
Help

Dataset Information

19 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Accomplishments in 2008 in the management of hepatobiliary cancers.

ABSTRACT: HEPATOCELLULAR CARCINOMA: EpidemiologyManagement of HCC-Standard Approaches and Reports During the Past Year SurgeryLocoregional Treatment Local AblationChemoembolizationOther Local Treatment ModalitiesSystemic TreatmentClinical Trial DesignBasic Science and Biomarkers Basic and Translational SciencePrognostic and Predictive Markers Prognostic MarkersPredictive MarkersAccomplishments and Future DirectionsApplication of the AccomplishmentsFuture Directions BILIARY TRACT CANCERS: Overview of the DiseaseManagement of Biliary Tract Cancers-Current Approaches and Reports During the Past Year Surgical Resection and Adjuvant TherapySystemic Therapy for Unresectable or Metastatic Biliary Tract Cancer Cytotoxic ChemotherapyCytotoxic Chemotherapy in Combination With Targeted AgentSingle-Agent Targeted TherapyCombination of Targeted AgentsBiologyFuture Directions.

SUBMITTER: Zhu AX

PROVIDER: S-EPMC2791389 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Accomplishments in 2008 in the management of hepatobiliary cancers.

Zhu Andrew X AX El-Khoueiry Anthony A Llovet Josep M JM

Gastrointestinal cancer research : GCR 20090901 5 Supplement 2

HEPATOCELLULAR CARCINOMA: EpidemiologyManagement of HCC-Standard Approaches and Reports During the Past Year SurgeryLocoregional Treatment Local AblationChemoembolizationOther Local Treatment ModalitiesSystemic TreatmentClinical Trial DesignBasic Science and Biomarkers Basic and Translational SciencePrognostic and Predictive Markers Prognostic MarkersPredictive MarkersAccomplishments and Future DirectionsApplication of the AccomplishmentsFuture Directions BILIARY TRACT CANCERS: Overview of the D ...[more]

PMID: 20011562

Similar Datasets

Accomplishments in 2008 in the management of esophageal cancer.

Project description:Overview of the Disease ProcessIncidencePrognostic or Predictive FactorsCurrent General Therapy StandardsSurgeryCombined Treatment ModalitiesAccomplishments in 2008TherapyBiomarkers & Basic ScienceWhat Needs to be DoneApplications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture DirectionsComments on ResearchObstacles to Progress.

| S-EPMC2791390 | biostudies-literature

Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Project description:Overview of the Disease ProcessIncidencePrognostic FactorsGeneral Therapy StandardsAccomplishments and Lack of Accomplishments During the YearSomatostatin AnalogsPeptide Receptor-Targeted TherapySelective Internal Radiotherapy (SIRT)CYTOTOXIC THERAPIES: TemozolomideVEGF Pathway InhibitorsmTOR InhibitorsDevelopment of BiomarkersWhat Needs to be Done (Application of the Accomplishments)Controversies and DisagreementsHistologic Classification and Staging of Neuroendocrine TumorsClinical Trial Design and End PointsFuture Directions.

| S-EPMC2791386 | biostudies-literature

Accomplishments in 2008 in the management of localized gastric cancer.

Project description:Overview of the Disease ProcessIncidencePrognostic or Predictive FactorsCurrent General Therapy StandardsSurgeryAdjuvant ChemoradiationPerioperative ChemotherapyAdjuvant Oral Fluoropyrimidine MonotherapyAccomplishments in 2008TherapyBiomarkers and Basic ScienceWhat Needs to Be DoneApplications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsCurrent and Future DirectionsComments on ResearchObstacles to Progress.

| S-EPMC2791387 | biostudies-literature

Accomplishments in 2008 in the management of gastrointestinal stromal tumors.

Project description:Overview of the Disease ProcessIncidencePrognosisPredictive MarkersCurrent General Therapy Standards in North America and EuropeLocalized or Potentially Resectable DiseaseUnresectable or Metastatic DiseaseAccomplishments During the YearTherapySurgical Issues and Perioperative TherapyImatinibSunitinibNew DrugsBiomarkersBasic and Other Translational ScienceWhat Needs to Be DoneFuture DirectionsComments on ResearchObstacles to Progress.

| S-EPMC2791388 | biostudies-literature

Accomplishments in 2008 in the management of advanced gastroesophageal cancer.

Project description:Overview of the Disease Process IncidencePrognosisPrognostic or Predictive FactorsCurrent General Therapy Standards Regional VariationsEvidence for Individual AgentsAccomplishments in 2008 TherapyBiomarkersBasic ScienceWhat Needs to be Done Applications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture Directions Comments on ResearchObstacles to Progress.

| S-EPMC2791384 | biostudies-literature

Accomplishments in 2008 in the management of curable metastatic colorectal cancer.

Project description:Overview of the Disease IncidencePrognosisCurrent Therapy Standards Colorectal Liver Metastases (CRLM) Resectable TumorsStrategies to Convert Nonresectable Liver Metastases to Resectable StatusSynchronous Colorectal Liver MetastasesPredictors of Survival After Resection of CRLMPeritoneal Carcinomatosis (PC) From Colorectal CancerColorectal Pulmonary Metastases (CRPM)Colorectal Liver Metastases With Extrahepatic DiseaseAccomplishments (or Lack of Accomplishments) During the Year Therapy New Staging SystemSystemic Chemotherapy in Resectable Liver MetastasesSystemic Chemotherapy in Nonresectable Liver MetastasesSelective Internal Radiation Therapy (SIRT)Selection of Patients for Liver ResectionRadiofrequency AblationBiomarkersWhat Needs To Be Done? Optimizing Patient CareFuture Directions Comments on ResearchObstacles to Overcome.

| S-EPMC2791382 | biostudies-literature

Accomplishments in 2008 in the adjuvant treatment of colon cancer.

Project description:Overview of the Disease IncidencePrognosisCurrent General Therapy Standards StagingLymph Node ExcisionStage III DiseaseStage II DiseaseMolecular MarkersAccomplishments During the Year Therapy Cytotoxic ChemotherapyChemotherapy Plus Targeted TherapySpecial PopulationsBasic Science-BiomarkersMethodologyWhat Needs to Be Done Application of the AccomplishmentsControversies and DisagreementsFuture Directions Comments on ResearchObstacles to Progress.

| S-EPMC2791381 | biostudies-literature

Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.

Project description:Overview of the DiseaseIncidencePrognosisCurrent Treatment StandardsCytotoxic TherapyTargeted TherapySalvage TherapyAccomplishments or Lack of AccomplishmentsTherapySalvage TherapyBiomarkersApplication of the AccomplishmentsFuture DirectionsCurrent Basic ResearchOngoing Clinical StudiesMajor Obstacles to Progress in Drug DevelopmentGemcitabine PlatformChoice of Molecular TargetsPatient Selection.

| S-EPMC2791391 | biostudies-literature

Accomplishments in 2008 in the adjuvant treatment of rectal cancer.

Project description:Overview of the Disease IncidencePrognostic FactorsCurrent General Therapy Standards Surgery(Neo) Adjuvant Radiotherapy and ChemotherapyAccomplishments During the Year Time Duration Between Radiotherapy and SurgeryHistopathology Post-Neoadjuvant TherapyMetabolic Imaging During Neoadjuvant TherapyNew Drugs in Combination with RadiotherapyNew StrategiesFuture Strategies ControversiesComments on ResearchObstacles to Progress.

| S-EPMC2791392 | biostudies-literature

Germline Genetic Associations for Hepatobiliary Cancers.

Project description:Hepatobiliary cancers (HBCs) include hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma, which originate from the liver, bile ducts, and gallbladder, respectively. They are responsible for a substantial burden of cancer-related deaths worldwide. Despite knowledge of risk factors and advancements in therapeutics and surgical interventions, the prognosis for most patients with HBC remains bleak. There is evidence from familial aggregation and case-control studies to suggest a familial risk component in HBC susceptibility. Recent progress in genomics research has led to the identification of germline variants including single nucleotide polymorphisms (SNPs) and pathogenic or likely pathogenic (P/LP) variants in cancer-associated genes associated with HBC risk. These findings emerged from genome-wide association studies and next-generation sequencing techniques such as whole-exome sequencing. Patients with other cancer types, including breast, colon, ovarian, prostate, and pancreatic cancer, are recommended by guidelines to undergo germline genetic testing, but similar recommendations are lagging in HBC. This prompts the question of whether multi-gene panel testing should be integrated into clinical guidelines for HBC management. Here, we review the hereditary genetics of HBC, explore studies investigating SNPs and P/LP variants in HBC patients, discuss the clinical implications and potential for personalized treatments and impact on patient's family members, and conclude that additional studies are needed to examine how genetic testing can be applied clinically.

| S-EPMC10899027 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data